These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

209 related items for PubMed ID: 15769089

  • 21. Antitumor activity of adriamycin (hydrazone-linked) immunoconjugates compared with free adriamycin and specificity of tumor cell killing.
    Braslawsky GR, Edson MA, Pearce W, Kaneko T, Greenfield RS.
    Cancer Res; 1990 Oct 15; 50(20):6608-14. PubMed ID: 2208123
    [Abstract] [Full Text] [Related]

  • 22. Growth-inhibitory effects of human anti-insulin-like growth factor-I receptor antibody (A12) in an orthotopic nude mouse model of anaplastic thyroid carcinoma.
    Wang Z, Chakravarty G, Kim S, Yazici YD, Younes MN, Jasser SA, Santillan AA, Bucana CD, El-Naggar AK, Myers JN.
    Clin Cancer Res; 2006 Aug 01; 12(15):4755-65. PubMed ID: 16899627
    [Abstract] [Full Text] [Related]

  • 23. Preclinical evaluation of LU 79553: a novel bis-naphthalimide with potent antitumor activity.
    Bousquet PF, Braña MF, Conlon D, Fitzgerald KM, Perron D, Cocchiaro C, Miller R, Moran M, George J, Qian XD.
    Cancer Res; 1995 Mar 01; 55(5):1176-80. PubMed ID: 7867004
    [Abstract] [Full Text] [Related]

  • 24. Potent antitumor 9-anilinoacridines bearing an alkylating N-mustard residue on the anilino ring: synthesis and biological activity.
    Bacherikov VA, Chou TC, Dong HJ, Zhang X, Chen CH, Lin YW, Tsai TJ, Lee RZ, Liu LF, Su TL.
    Bioorg Med Chem; 2005 Jun 02; 13(12):3993-4006. PubMed ID: 15911312
    [Abstract] [Full Text] [Related]

  • 25. chFRP5-ZZ-PE38, a large IgG-toxin immunoconjugate outperforms the corresponding smaller FRP5(Fv)-ETA immunotoxin in eradicating ErbB2-expressing tumor xenografts.
    Mazor Y, Noy R, Wels WS, Benhar I.
    Cancer Lett; 2007 Nov 08; 257(1):124-35. PubMed ID: 17698286
    [Abstract] [Full Text] [Related]

  • 26. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate.
    Hamblett KJ, Senter PD, Chace DF, Sun MM, Lenox J, Cerveny CG, Kissler KM, Bernhardt SX, Kopcha AK, Zabinski RF, Meyer DL, Francisco JA.
    Clin Cancer Res; 2004 Oct 15; 10(20):7063-70. PubMed ID: 15501986
    [Abstract] [Full Text] [Related]

  • 27. Cure of SCID mice bearing human B-lymphoma xenografts by an anti-CD74 antibody-anthracycline drug conjugate.
    Griffiths GL, Mattes MJ, Stein R, Govindan SV, Horak ID, Hansen HJ, Goldenberg DM.
    Clin Cancer Res; 2003 Dec 15; 9(17):6567-71. PubMed ID: 14695162
    [Abstract] [Full Text] [Related]

  • 28. Therapeutic efficacy and tumor dose estimations in radioimmunotherapy of intraperitoneally growing OVCAR-3 cells in nude mice with (211)At-labeled monoclonal antibody MX35.
    Elgqvist J, Andersson H, Bäck T, Hultborn R, Jensen H, Karlsson B, Lindegren S, Palm S, Warnhammar E, Jacobsson L.
    J Nucl Med; 2005 Nov 15; 46(11):1907-15. PubMed ID: 16269606
    [Abstract] [Full Text] [Related]

  • 29. [Antitumor effect of lidamycin-containing monoclonal antibody immunoconjugate with downsized-molecule].
    Liu XY, Zhen YS.
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2001 Dec 15; 23(6):563-7. PubMed ID: 12901099
    [Abstract] [Full Text] [Related]

  • 30. MUC1/X protein immunization enhances cDNA immunization in generating anti-MUC1 alpha/beta junction antibodies that target malignant cells.
    Rubinstein DB, Karmely M, Ziv R, Benhar I, Leitner O, Baron S, Katz BZ, Wreschner DH.
    Cancer Res; 2006 Dec 01; 66(23):11247-53. PubMed ID: 17145869
    [Abstract] [Full Text] [Related]

  • 31. Preclinical efficacy and pharmacokinetics of AP5346, a novel diaminocyclohexane-platinum tumor-targeting drug delivery system.
    Rice JR, Gerberich JL, Nowotnik DP, Howell SB.
    Clin Cancer Res; 2006 Apr 01; 12(7 Pt 1):2248-54. PubMed ID: 16609041
    [Abstract] [Full Text] [Related]

  • 32. [Antitumor effects of the immunoconjugate composed of lidamycin and monoclonal antibody 3G11].
    Wang FQ, Shang BY, Zhen YS.
    Yao Xue Xue Bao; 2003 Jul 01; 38(7):515-9. PubMed ID: 14515796
    [Abstract] [Full Text] [Related]

  • 33. Novel acid labile COL1 trityl-linked difluoronucleoside immunoconjugates: synthesis, characterization, and biological activity.
    Patel VF, Hardin JN, Mastro JM, Law KL, Zimmermann JL, Ehlhardt WJ, Woodland JM, Starling JJ.
    Bioconjug Chem; 1996 Jul 01; 7(4):497-510. PubMed ID: 8853464
    [Abstract] [Full Text] [Related]

  • 34. [Radioimmunotherapy with 131 I-labeled humanized anti-HBsAg Fab and anti-nucleus antigen monoclonal antibody chTNT in nude mice bearing human hepatocellular carcinoma].
    DU YF, Luo RC, Li GP, Li AM, Ding XM, Yan X, Huang K.
    Nan Fang Yi Ke Da Xue Xue Bao; 2008 Mar 01; 28(3):460-2. PubMed ID: 18359714
    [Abstract] [Full Text] [Related]

  • 35. Antitumor efficacy of a combination of CMC-544 (inotuzumab ozogamicin), a CD22-targeted cytotoxic immunoconjugate of calicheamicin, and rituximab against non-Hodgkin's B-cell lymphoma.
    DiJoseph JF, Dougher MM, Kalyandrug LB, Armellino DC, Boghaert ER, Hamann PR, Moran JK, Damle NK.
    Clin Cancer Res; 2006 Jan 01; 12(1):242-9. PubMed ID: 16397048
    [Abstract] [Full Text] [Related]

  • 36. Preclinical efficacy of the camptothecin-polymer conjugate IT-101 in multiple cancer models.
    Schluep T, Hwang J, Cheng J, Heidel JD, Bartlett DW, Hollister B, Davis ME.
    Clin Cancer Res; 2006 Mar 01; 12(5):1606-14. PubMed ID: 16533788
    [Abstract] [Full Text] [Related]

  • 37. A novel humanized MUC1 antibody-drug conjugate for the treatment of trastuzumab-resistant breast cancer.
    Wu G, Li L, Qiu Y, Sun W, Ren T, Lv Y, Liu M, Wang X, Tao H, Zhao L, Cao J, He L, Li H, Gu H.
    Acta Biochim Biophys Sin (Shanghai); 2021 Dec 08; 53(12):1625-1639. PubMed ID: 34586349
    [Abstract] [Full Text] [Related]

  • 38. In vitro and in vivo comparison of a randomly coupled antibody fragment-enzyme conjugate with a site-specific conjugate.
    Werlen RC, Offord RE, Blakey DC, East SJ, Melton RG, Rose K.
    Biomed Pept Proteins Nucleic Acids; 1995 Dec 08; 1(5):251-4. PubMed ID: 9575348
    [Abstract] [Full Text] [Related]

  • 39. Antitumor activity of L/1C2-4-desacetylvinblastine-3-carboxhydrazide immunoconjugate in xenografts.
    Johnson DA, Baker AL, Laguzza BC, Fix DV, Gutowski MC.
    Cancer Res; 1990 Mar 15; 50(6):1790-4. PubMed ID: 2306731
    [Abstract] [Full Text] [Related]

  • 40. A human antibody-drug conjugate targeting EphA2 inhibits tumor growth in vivo.
    Jackson D, Gooya J, Mao S, Kinneer K, Xu L, Camara M, Fazenbaker C, Fleming R, Swamynathan S, Meyer D, Senter PD, Gao C, Wu H, Kinch M, Coats S, Kiener PA, Tice DA.
    Cancer Res; 2008 Nov 15; 68(22):9367-74. PubMed ID: 19010911
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.